Extended indication Hyperkaliëmie in CHF en CKD in volwassenen.
Therapeutic value No judgement
Registration phase Unknown

Product

Active substance Patiromer
Domain Metabolism and Endocrinology
Main indication Metabolic diseases
Extended indication Hyperkaliëmie in CHF en CKD in volwassenen.
Proprietary name Veltassa
Manufacturer Vifor
Mechanism of action Unknown
Route of administration Oral
Therapeutical formulation Powder for oral suspension
Budgetting framework Extramural (GVS)
Additional remarks Patiromer bindt kalium in het maagdarmkanaal. Risico als blijkt dat meer patienten het gebruiken dan verwacht (naast patienten met nierinsufficientie ook patienten met hartfalen).

Registration

Registration route Centralised (EMA)
Type of trajectory Normal trajectory
Particularity Unknown
ATMP Unknown
Submission date April 2016
Expected Registration July 2017
Orphan drug No
Registration phase Unknown
Additional remarks Geregistreerd in juli 2017, nog niet beschikbaar op de Nederlandse markt.

Therapeutic value

Current treatment options De behandeling van eerste keus is intraveneuze toediening van calciumgluconaat.
Therapeutic value No judgement

This assessment does not indicate any potential inclusion in the package.

Frequency of administration 1 times a day
Dosage per administration 8,4-16,8-25,2 g
Additional remarks Startdosis is 8,4 g, mag worden opgehoogd tot max. 25,2 g per dag.

Expected patient volume per year

Patient volume

Market share is generally not included unless otherwise stated.

Additional remarks Gering aantal patiënten

Expected cost per patient per year

Cost 3,500.00 - 4,500.00

This amount gives an indication of the total cost. It is the result of the average expected patient volume times the average cost per patient. both per year.

References Fabrikant
Additional remarks Fabrikant (nov 2017): Prijs bij GVS aanvraag €3500 - 4500 pppj.

Potential total cost per year

Off label use

Off label use Unknown

Indication extension

Indication extensions Unknown

Other information